A pilot study of visceral fat and its association with adipokines, stool calprotectin and symptoms in patients with diverticulosis.
Adiponectin
/ blood
Adolescent
Adult
Aged
Aged, 80 and over
Body Mass Index
Diverticulum
/ epidemiology
Feces
/ chemistry
Female
Humans
Insulin Resistance
Intra-Abdominal Fat
/ physiopathology
Leukocyte L1 Antigen Complex
/ analysis
Magnetic Resonance Imaging
Male
Middle Aged
Pilot Projects
Young Adult
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
10
09
2018
accepted:
18
04
2019
entrez:
9
5
2019
pubmed:
9
5
2019
medline:
24
1
2020
Statut:
epublish
Résumé
Complications of diverticular disease are increasingly common, possibly linked to increasing obesity. Visceral fat could contribute to the development of symptomatic diverticular disease through its pro-inflammatory effects. The study had 2 aims. A) to develop a semi-automated algorithm to measure abdominal adipose tissue from 2-echo magnetic resonance imaging (MRI) data; B) to use this to determine if visceral fat was associated with bowel symptoms and inflammatory markers in patients with symptomatic and asymptomatic diverticular disease. An observational study measuring visceral fat using MRI together with serum adiponectin, leptin, stool calprotectin and patient-reported somatisation and bowel habit. Medical and imaging research centres of a university hospital. MRI scans were performed on 55 patients after an overnight fast measuring abdominal subcutaneous and visceral adipose tissue volumes together with small bowel water content (SBWC). Blood and stool samples were collected and patients kept a 2 week stool diary and completed a somatisation questionnaire. Difference in the volume of visceral fat between symptomatic and asymptomatic patients. There were no significant differences in visceral (p = 0.98) or subcutaneous adipose (p = 0.60) tissue between symptomatic and asymptomatic patients. However measured fat volumes were associated with serum adipokines. Adiponectin showed an inverse correlation with visceral adipose tissue (VAT) (Spearman ρ = -0.5, p = 0.0003), which correlated negatively with SBWC (ρ = -0.3, p = 0.05). Leptin correlated positively with subcutaneous adipose tissue (ρ = 0.8, p < 0.0001). Overweight patients (BMI > 25 kgm-2) showed a moderate correlation between calprotectin and VAT (ρ = 0.3, p = 0.05). Somatization scores were significantly higher in symptomatic patients (p < 0.0003). Increasing visceral fat is associated with lower serum adiponectin and increased faecal calprotectin suggesting a pro-inflammatory effect which may predispose to the development of complications of diverticulosis.
Sections du résumé
BACKGROUND
Complications of diverticular disease are increasingly common, possibly linked to increasing obesity. Visceral fat could contribute to the development of symptomatic diverticular disease through its pro-inflammatory effects.
OBJECTIVE
The study had 2 aims. A) to develop a semi-automated algorithm to measure abdominal adipose tissue from 2-echo magnetic resonance imaging (MRI) data; B) to use this to determine if visceral fat was associated with bowel symptoms and inflammatory markers in patients with symptomatic and asymptomatic diverticular disease.
DESIGN
An observational study measuring visceral fat using MRI together with serum adiponectin, leptin, stool calprotectin and patient-reported somatisation and bowel habit.
SETTING
Medical and imaging research centres of a university hospital.
PARTICIPANTS
MRI scans were performed on 55 patients after an overnight fast measuring abdominal subcutaneous and visceral adipose tissue volumes together with small bowel water content (SBWC). Blood and stool samples were collected and patients kept a 2 week stool diary and completed a somatisation questionnaire.
MAIN OUTCOME MEASURES
Difference in the volume of visceral fat between symptomatic and asymptomatic patients.
RESULTS
There were no significant differences in visceral (p = 0.98) or subcutaneous adipose (p = 0.60) tissue between symptomatic and asymptomatic patients. However measured fat volumes were associated with serum adipokines. Adiponectin showed an inverse correlation with visceral adipose tissue (VAT) (Spearman ρ = -0.5, p = 0.0003), which correlated negatively with SBWC (ρ = -0.3, p = 0.05). Leptin correlated positively with subcutaneous adipose tissue (ρ = 0.8, p < 0.0001). Overweight patients (BMI > 25 kgm-2) showed a moderate correlation between calprotectin and VAT (ρ = 0.3, p = 0.05). Somatization scores were significantly higher in symptomatic patients (p < 0.0003).
CONCLUSIONS
Increasing visceral fat is associated with lower serum adiponectin and increased faecal calprotectin suggesting a pro-inflammatory effect which may predispose to the development of complications of diverticulosis.
Identifiants
pubmed: 31067253
doi: 10.1371/journal.pone.0216528
pii: PONE-D-18-24732
pmc: PMC6505945
doi:
Substances chimiques
ADIPOQ protein, human
0
Adiponectin
0
Leukocyte L1 Antigen Complex
0
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0216528Subventions
Organisme : Department of Health
ID : PDF-2012-05-431
Pays : United Kingdom
Organisme : Department of Health
ID : BRU 2011-2022
Pays : United Kingdom
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Aliment Pharmacol Ther. 2010 Sep;32(6):811-20
pubmed: 20629976
Dig Dis. 2012;30(1):70-4
pubmed: 22572689
Gastroenterology. 2009 Apr;136(4):1198-205
pubmed: 19185583
Phys Med Biol. 2007 Dec 7;52(23):6909-22
pubmed: 18029983
Gastroenterology. 2016 Feb 13;:
pubmed: 27144634
Endocr Rev. 2000 Dec;21(6):697-738
pubmed: 11133069
Neurogastroenterol Motil. 2004 Aug;16(4):413-9
pubmed: 15305996
Gastroenterology. 2009 Jan;136(1):115-122.e1
pubmed: 18996378
Mutagenesis. 2010 May;25(3):243-7
pubmed: 20106932
NMR Biomed. 2015 May;28(5):583-90
pubmed: 25808071
J Magn Reson Imaging. 2010 Feb;31(2):430-9
pubmed: 20099357
Aliment Pharmacol Ther. 2010 Sep;32(5):655-63
pubmed: 20626735
J Magn Reson Imaging. 2011 Oct;34(4):852-60
pubmed: 21769972
Proc R Soc Med. 1968 Sep;61(9):932-4
pubmed: 5679019
J Clin Endocrinol Metab. 2007 Jun;92(6):2240-7
pubmed: 17374712
Colorectal Dis. 2011 Apr;13 Suppl 3:1-11
pubmed: 21366820
Biomed Res Int. 2014;2014:658913
pubmed: 25110685
Gut. 2012 Jan;61(1):95-100
pubmed: 21551188
Annu Rev Pharmacol Toxicol. 2005;45:119-46
pubmed: 15822173
J Magn Reson Imaging. 2013 May;37(5):1144-50
pubmed: 23124651
Int J Obes (Lond). 2006 May;30(5):844-52
pubmed: 16418756
Mucosal Immunol. 2012 Sep;5(5):580-91
pubmed: 22569302
Scand J Gastroenterol. 1999 Jan;34(1):50-4
pubmed: 10048733
Gastroenterology. 2012 Feb;142(2):266-72.e1
pubmed: 22062360
Obesity (Silver Spring). 2009 Mar;17(3):424-30
pubmed: 19219061
NMR Biomed. 2011 Jan;24(1):17-24
pubmed: 20672389
Dis Colon Rectum. 2008 Apr;51(4):450-5
pubmed: 18157570
Br J Surg. 2008 Feb;95(2):195-8
pubmed: 17939130
Diabetes. 2006 Jun;55(6):1554-61
pubmed: 16731817
J Magn Reson Imaging. 2012 Dec;36(6):1421-34
pubmed: 22911921
Obesity (Silver Spring). 2010 Jul;18(7):1336-40
pubmed: 19910940
Med Biol Eng Comput. 2015 Nov;53(11):1247-54
pubmed: 26245254
Horm Metab Res. 1996 Dec;28(12):690-3
pubmed: 9013743
Gut. 2011 Feb;60(2):219-24
pubmed: 20940283
Magn Reson Med. 2011 Jan;65(1):96-107
pubmed: 20860006
Obesity (Silver Spring). 2007 Sep;15(9):2240-4
pubmed: 17890492
Neurogastroenterol Motil. 2012 Apr;24(4):318-e163
pubmed: 22276853
Int J Colorectal Dis. 2009 Jan;24(1):49-55
pubmed: 18941760
Gastroenterology. 2006 Apr;130(5):1480-91
pubmed: 16678561
Magn Reson Imaging. 2010 May;28(4):520-6
pubmed: 20096526
Ann Surg. 2009 Feb;249(2):210-7
pubmed: 19212172
Neurogastroenterol Motil. 2015 Mar;27(3):305-12
pubmed: 25703217
J Magn Reson Imaging. 2010 Jul;32(1):204-10
pubmed: 20575078
J Magn Reson Imaging. 2015 Apr;41(4):924-34
pubmed: 24803305
Mol Med. 2011;17(11-12):1157-67
pubmed: 21738950
Gut Liver. 2013 Sep;7(5):532-8
pubmed: 24073310
J Clin Gastroenterol. 2019 May/Jun;53(5):e178-e185
pubmed: 29356787
Ann Transl Med. 2013 Jul 1;1(2):14
pubmed: 24432301
J Magn Reson Imaging. 2011 Aug;34(2):474-9
pubmed: 21780238
Am J Gastroenterol. 2015 Feb;110(2):310-9
pubmed: 25583325
Neurogastroenterol Motil. 2014 Jan;26(1):124-30
pubmed: 24131490
J Clin Invest. 2003 Dec;112(12):1796-808
pubmed: 14679176
PLoS One. 2012;7(3):e34233
pubmed: 22457829